Pembrolizumab, Belzutifan, and Lenvatinib for Kidney Cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of three medicines—pembrolizumab (a drug that helps your immune system fight cancer), belzutifan, and lenvatinib (drugs that slow tumor growth)—in patients with early-stage kidney cancer who are candidates for surgery. The goal is to see if this combination can improve outcomes before or alongside surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have kidney cancer (renal cell carcinoma) with a clear cell type, confirmed by biopsy
- Your cancer must be locally advanced (larger tumors or spread to lymph nodes, but not distant spread)
- You must be a candidate for curative surgery (partial or complete kidney removal) as determined by a surgeon
- You must be in good overall health (ECOG performance status 0–1) with controlled blood pressure and adequate organ function
- You cannot have received prior immunotherapy (anti-PD-1, anti-PD-L1) or systemic cancer treatment in the past 3 years
- You must provide a tissue sample (biopsy) for research purposes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving pembrolizumab (an immune medicine) and lenvatinib (a targeted medicine) before surgery can shrink or better treat renal cell carcinoma. The goal is to improve surgical outcomes and help the body fight the cancer.
This Phase 2 trial tests whether pembrolizumab plus axitinib can shrink kidney cancer before surgery, when there is tumor growth into the inferior vena cava (IVC). It may help make the operation easier and improve chances of long-term control.
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
This trial tests combining the immunotherapy drug pembrolizumab with the targeted therapy lenvatinib for people with advanced clear cell kidney cancer that returned after completing pembrolizumab as an early treatment after surgery. It aims to see if this combination can shrink or control the cancer.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
This trial tests whether the immunotherapy drug pembrolizumab can help prevent kidney cancer from coming back after surgery. It is for people with a less common type of kidney cancer called non-clear cell renal cell carcinoma that was at a higher stage or had spread but was fully removed.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.